CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?

Future Medicinal Chemistry - United Kingdom
doi 10.4155/fmc-2018-0389
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Science Ltd

Related search

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

Emerging Data and Future Directions for CDK4/6 Inhibitor Treatment of Patients With Hormone Receptor Positive HER2-non-amplified Metastatic Breast Cancer

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

One Size Does Not Fit All

Journal of College Orientation, Transition, and Retention
2019English

Rapamycin – “One Size Does Not Fit All”

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy